Should site-neutral payment rules and policies be extended to commercial payers, payment for physician-administered drugs, and services delivered in on-campus hospital outpatient departments?
We want to know what you’re thinking! Every Tuesday morning, the editors of Managed Healthcare Executive are posing a question to our readers about a timely issue in U.S. healthcare. We'll tally your answers and publish the results on Friday by 4 p.m. ET.
Some background on this week’s question
Payment for outpatient services has traditionally varied depending on where the services were delivered. Typically, they have been higher at hospital outpatient facilities than at physician offices. But as hospitals have bought physician practices and expanded their outpatient facilities, payers and others have pushed for “site-neutral” payment that pays the same amount for the service, regardless of where it is delivered. Medicare already has some site-neutral payment policies.
Now Congress and regulators are considering legislation and rules that would extend site-neutral payment further to include physician-administered drugs and outpatient facilities located on hospital campuses. Some proposals would also apply site-neutral payment rules to commercial payers.
Hospitals and some other groups are fighting site-neutral payment, arguing that patients seen in hospital facilities receive more coordinated care and are often more medically complex.
Should site-neutral payment rules and policies be extended to commercial payers, payment for physician-administered drugs, and services delivered in on-campus hospital outpatient departments?
FDA Update for Week of April 22, 2024: Second Gene Therapy for Hemophilia B
April 27th 2024This week, the FDA has approved several products, including Beqvez, the second gene therapy hemophilia B; Ojemda for children with brain tumors; an additional indication for Lutathera for adolescents with neuroendocrine tumors; and a bladder cancer immunotherapy. The agency has also issued a complete response letter for pz-cel to treat epidermolysis bullosa.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen